These findings unveil a crucial interaction between histone marks and transcriptional modulation during the progression of TNBC, thereby supporting strategies targeting the KMT2D‐H3K4me1‐YBX1 axis to treat breast cancer. The gene discussed is KMT2D; the disease is breast cancer.